A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Abstract Text:

L W Chu,P Y Yik,W Mok,C P Chung,L W Chu,P Y Yik,W Mok,C P Chung,

There was no long-term clinical study on galantamine in Alzheimer's disease (AD) in the Asian population. The objectives of this study were to evaluate the efficacy of galantamine on cognitive function, daily functioning, behavioural symptoms and its safety in Chinese AD patients. This was a 2-year open-label clinical trial. The inclusion criteria were patients with probable AD by the NINCDS-ADRDA criteria. A historical control group (n = 19) of AD patients with no galantamine or other cholinesterase inhibitor therapy was employed. In the galantamine group, 33 and 32 subjects had completed a 1-year and 2-year follow up, respectively. Within the galantamine group and at a 6-month follow up, the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog score) showed an improvement of 2.9 +/- 1.18 (p = 0.019, paired t-test) but remained the same at 1 and 2 years. The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) deteriorated by 4.31 +/- 2.06 (p = 0.044, paired t-test) at 6 months but showed no significant decline at 1 and 2 years vs. baseline. The Neuropsychiatric Inventory (NPI) score also showed a significant deterioration of 5 +/- 1.99 (p = 0.017, paired t-test) at 6 months, 8.06 +/- 1.97 (p < 0.001, paired t-test) at 1 year and 7.31 +/- 1.76 at 2 years. Comparison between the two groups showed a statistically significant improvement in the 1-year ADAS-cog score but decline in the NPI score in the galantamine vs. control groups. Adverse effects were commonly mild. In Chinese mild-moderate AD patients, galantamine showed beneficial effects mainly on the cognitive function.

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Publishing Authors By Initials

LW Chu,PY Yik,W Mok,CP Chung,LW Chu,PY Yik,W Mok,CP Chung,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: International journal of clinical practice

VOLUME: 61

Page Numbers: 403-10

Journal Abbreviation: Int. J. Clin. Pract.

ISSN: 1368-5031

DAY: 22

MONTH: Mar

YEAR: 2007

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9712381

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.

AFFILIATION: Division of Geriatrics, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China. lwchu@hlucc.hku.hk

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Clin Pract

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong Related Publications

• A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
• Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis.
• Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.
• Distribution of respiratory mucin proteins in human nasal mucosa.
• Effect of superoxide dismutase on the development of preimplantation mouse embryos.
• Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer.
• Experience of Middle- and Old-Aged Women's Aging.
• Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung.
• Expression of respiratory mucins in fatal status asthmaticus and mild asthma.
• Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
• IGF-1 protects intestinal epithelial cells from oxidative stress-induced apoptosis.
• Importance of hyperexcitability of DRG neurons in neuropathic pain.
• Improved results using extensively coated THA stems at minimum 5-year followup.
• Inhibition of transforming growth factor-beta/Smad signaling by phosphatidylinositol 3-kinase pathway.
• MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
• Mucus and fatal asthma.
• Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
• Oxidative stress-induced intestinal epithelial cell apoptosis is mediated by p38 MAPK.
• Pellegrini-Stieda disease: a heterogeneous disorder not synonymous with ossification/calcification of the tibial collateral ligament-anatomic and imaging investigation.
• Postnatal depression: an update.
• Role of RacC for the regulation of WASP and phosphatidylinositol 3-kinase during chemotaxis of Dictyostelium.
• The WPA Regional Meeting "Science and Humanism" (Seoul, April 18-21, 2007).
• The clinical implementation of respiratory-gated intensity-modulated radiotherapy.
• The role of reactive oxygen species (ROS) in persistent pain.
• Using the PHQ-9 for depression screening and treatment monitoring for Chinese Americans in primary care.
• Vanadium-catalyzed addition of propargyl alcohols and imines.
• [Development of a critical thinking disposition scale for nursing students]
• [Massive gastric ulcer bleeding in a healthy full term infant]
• [Modulation of tropoelastin expression in cultured human dermal fibroblasts by heat shock.]
• [Resistance to adefovir in patients with chronic hepatitis B]